Bonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses

Stock News

Jul 22

Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.

According to the lapsed document, Bonsun Pharmaceuticals is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1170452620"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170452620\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170452620?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170452620","market":"us","top_or_hot":-1,"title":"Bonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses","media":"Stock News","content":"<p>Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.<br><br>According to the lapsed document, <b>Bonsun Pharmaceuticals</b> is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-22 09:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.<br><br>According to the lapsed document, <b>Bonsun Pharmaceuticals</b> is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FRHC","symbol_name":"Euronext CAC Health Care","start_time":0,"source_url":"","article_id":"1170452620","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170452620","pubTimestamp":1784683099,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FRHC":"Euronext CAC Health Care","01477":"欧康维视生物-B","BK4127":"投资银行业与经纪业","KCE":"SPDR KBW Capital Markets ETF","REDS":"RPM Republican Senate ETF","BK1191":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","KCAI":"KraneShares China Alpha Index ETF","IPOS":"Renaissance International IPO ETF","VXUS":"国际股票ETF-Vanguard"},"translate_title":"邦生制药香港IPO招股说明书失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"IPOS":1,"FRHC":1,"01477":1,"KCE":1,"REDS":1,"KCAI":1},"content_text":"Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.According to the lapsed document, Bonsun Pharmaceuticals is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}